| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5481475f87f83470947c3f0480725606
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6559fb9f2fbe91cc4f6ea37808625e5e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-325
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5041
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2005-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2010-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3dc37b0eabbeaa924ac816a44309bbc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93493c36e196a78d5d9bb1ef9fec5179 |
| publicationDate |
2010-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2389798-C2 |
| titleOfInvention |
Method for treatment with bucindolol based on genotype definition |
| abstract |
FIELD: biotechnologies. ^ SUBSTANCE: application of medicinal agent is explained, which contains bucindolol, to produce medicine to treat patient suffering cardiovascular disease. In which specified patient lacks detected levels of protein 1AR with glycine in position 389. Specified patient is homozygous by cysteine in position 1165 in coding nucleotide sequence of both allels 1AR. Specified patient lacks detected levels of protein 2ACAR with deletion in positions 322-325. Or specified patient is homozygous in position 964-975 in coding nucleotide sequence of both allels 2ACAR of wild type. Medicinal agent is described, which contains bucindolol, to treat patient suffering cardiovascular disease, where specified patients demonstrates above-described criteria. Method for treatment of impaired cardiac function is presented with application of bucindolol based on genotype of patient with polymorphism in genes of adrenergic receptors including gene 1-adrenergic receptor (1AR) and 2c-adrenergic receptor (2cAR). ^ EFFECT: invention may be used to treat impaired cardiac function in patients suffering diabetes. ^ 15 cl, 29 dwg, 9 tbl, 11 ex |
| priorityDate |
2004-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |